Conferences - Results from #1180

Viewing 1181-1200 of 11745 articles

ESMO 2023: HRD Complete, a Novel Next Generation Sequencing Assay for Detecting Homologous Recombination Repair Gene Alterations in Prostate Cancer

ESMO 2023: Invited Discussant: Phase 3 THOR Study & THOR-2 Cohort 1

ESMO 2023: A Novel Machine Learning Based Method to Detect Homozygous Deletion of Homologous Recombination Repair (HRR) Genes in Prostate Cancer

Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) vs Chemotherapy

ESMO 2023: First Real-Life Data on 177Lu-PSMA-617: Descriptive Analysis on the Largest Metastatic Castration Resistant Prostate Cancer Cohort Treated in Early Access in France

ESMO 2023: ICRA: Efficacy of Paclitaxel with Tremelimumab +/- Durvalumab in Metastatic Urothelial Carcinoma After Progression on Platinum Chemotherapy and Anti-PD-(L)1

ESMO 2023: The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan plus Enfortumab Vedotin as ≥ Second Line Therapy for Metastatic Urothelial Carcinoma

ESMO 2023: Phase 1/2 Trial of Oral EPI-7386 in Combination with Enzalutamide Compared to Enzalutamide Alone in mCRPC Subjects: Current Phase 1 results

ESMO 2023: THOR Phase 3: Results of Erdafitinib vs Pembrolizumab in Pretreated Patients With Advanced or Metastatic Urothelial Cancer With Select Fibroblast Growth Factor Receptor Alterations

ESMO 2023: THOR-2 Cohort 1: Results of Erdafitinib vs Intravesical Chemotherapy for High-Risk Non Muscle Invasive Bladder Cancer with Select FGFR Alterations Who Received Prior BCG Treatment

ESMO 2023: Association of Health-Related Quality of Life with Efficacy Outcomes in the VISION Study of Patients with mCRPC

ESMO 2023: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR Prostate Cancer – A Phase 3 Study

ESMO 2023: New Therapeutic Targets in Advanced Renal Cell Carcinoma (RCC) and Data from Sequencing Trials

ESMO 2023: What is the Role of Localized Therapies in Metastatic Renal Cell Carcinoma (RCC)?

ESMO 2023: Invited Discussant: Final Results of RADICALS RT & Interim Results from a Phase 1 Study of AMG 509 in Metastatic Castration Resistant Prostate Cancer (mCRPC)

ESMO 2023: Invited Discussant: Is More Always Better?

ESMO 2023: Refining Risk Stratification in Patients Undergoing Radiotherapy and Long-Term ADT for High-Risk/locally Advanced Prostate Cancer: An Individual Patient Data Analysis of RCTs from the ICECaP Consortium

ESMO 2023: Enzalutamide and 177Lu-PSMA-617 in Poor-Risk Metastatic Castration-Resistant Prostate Cancer (mCRPC), a Randomized, Phase 2 Trial

ESMO 2023: STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Interim Results Phase 1 AMG 509 (Xaluritamig)

ESMO 2023: RADICALS RT Final Results: Timing of Radiotherapy After Radical Prostatectomy Randomised Controlled Trial

55
56
57
58
59
60
61
62
63
64